Haemonetics Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher A. Simon
- Full Time Employees
- 3,009
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 125 Summer Street Boston MA United States of America 02110
- IPO Date
- May 10, 1991
- CIK
- 0000313143
- Website
- haemonetics.com
- Similar Companies
- Business
- Haemonetics Corporation (NYSE: HAE) develops, manufactures and markets innovative medical technologies and software solutions that address blood management needs; the company offers automated blood collection and processing systems including the NexSys PCS plasmapheresis platform with Persona technology and Express Plus software, cell salvage autotransfusion devices such as the Cell Saver Elite+ with Intelligent Control, hemostasis analyzers like the TEG 6s with Global Hemostasis-HN cartridge, vascular closure systems including the VASCADE portfolio, interventional guidewires from SavvyWire and OptoWire via OpSens, esophageal cooling devices such as ensoETM from Attune Medical, and blood management software encompassing BloodTrack HaemoBank, SafeTrace Tx transfusion management and NexLynk DMS; Haemonetics serves hospitals, plasma collection centers, blood banks and surgical suites with products that enhance patient outcomes, improve operational efficiency and ensure blood safety. Founded in 1971 and headquartered in Boston, Massachusetts, the company maintains global operations across North America, Europe, Asia-Pacific and Latin America, with manufacturing facilities including sites in the United States and Mexico. In recent developments, Haemonetics announced in December 2024 a binding agreement to divest its Transfusion Medicine whole blood business—including blood collection, processing, filtration and transfusion solutions—to GVS S.p.A. for up to $67.1 million with closure expected in Q1 2025; the company completed acquisitions of Attune Medical in 2024 adding the ensoETM device, launched the TEG 6s Global Hemostasis-HN cartridge and earned CE Mark for SavvyWire in 2024, acquired OpSens Inc. in 2023 for guidewire technologies, and secured FDA clearances and international approvals for plasma and vascular products in 2023.
Company News
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
GEHC vs. HAE: Which Stock Is the Better Value Option?
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors
Here's Why Haemonetics (HAE) is a Strong Momentum Stock
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know
Haemonetics Q1 Earnings Call Highlights
Haemonetics Corporation (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates
Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment
New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths